New drug HEC89736 tested in blood cancer patients – study stopped early
NCT ID NCT04865458
First seen May 15, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called HEC89736 in 5 adults with B-cell blood cancers that had come back or stopped responding to treatment. The main goal was to check the drug's safety and how the body processes it. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL HEMATOLOGIC MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.